JPH0244320B2 - - Google Patents
Info
- Publication number
- JPH0244320B2 JPH0244320B2 JP57021905A JP2190582A JPH0244320B2 JP H0244320 B2 JPH0244320 B2 JP H0244320B2 JP 57021905 A JP57021905 A JP 57021905A JP 2190582 A JP2190582 A JP 2190582A JP H0244320 B2 JPH0244320 B2 JP H0244320B2
- Authority
- JP
- Japan
- Prior art keywords
- interferon
- solution
- human
- precipitate
- crude
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 239000002244 precipitate Substances 0.000 claims description 17
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 claims description 12
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 claims description 9
- 102000006992 Interferon-alpha Human genes 0.000 claims description 8
- 108010047761 Interferon-alpha Proteins 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- 108010050904 Interferons Proteins 0.000 description 46
- 102000014150 Interferons Human genes 0.000 description 45
- 229940079322 interferon Drugs 0.000 description 45
- 239000000243 solution Substances 0.000 description 28
- 238000000034 method Methods 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 11
- 238000005194 fractionation Methods 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 9
- 238000011084 recovery Methods 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000000605 extraction Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 238000002523 gelfiltration Methods 0.000 description 3
- 238000005342 ion exchange Methods 0.000 description 3
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 3
- 229940116357 potassium thiocyanate Drugs 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 210000004544 dc2 Anatomy 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- -1 iodo ions Chemical class 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000005373 porous glass Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57021905A JPS58140093A (ja) | 1982-02-13 | 1982-02-13 | α―インターフエロンの製法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57021905A JPS58140093A (ja) | 1982-02-13 | 1982-02-13 | α―インターフエロンの製法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58140093A JPS58140093A (ja) | 1983-08-19 |
| JPH0244320B2 true JPH0244320B2 (ko) | 1990-10-03 |
Family
ID=12068112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57021905A Granted JPS58140093A (ja) | 1982-02-13 | 1982-02-13 | α―インターフエロンの製法 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS58140093A (ko) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07211450A (ja) * | 1993-09-18 | 1995-08-11 | Daewoo Electron Co Ltd | 電子レンジ用マグネトロンのノイズ遮蔽装置 |
-
1982
- 1982-02-13 JP JP57021905A patent/JPS58140093A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07211450A (ja) * | 1993-09-18 | 1995-08-11 | Daewoo Electron Co Ltd | 電子レンジ用マグネトロンのノイズ遮蔽装置 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS58140093A (ja) | 1983-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2721699B2 (ja) | 肝炎蛋白質の精製 | |
| US5177194A (en) | Process for purifying immune serum globulins | |
| JP3018412B2 (ja) | 血漿蛋白の分画方法 | |
| JP3676370B2 (ja) | 濾過 | |
| HU202554B (en) | Process for lipophyl protheines | |
| NL7907791A (nl) | Werkwijze voor het zuiveren van interferon. | |
| US6797476B2 (en) | Process for the scaleable purification of plasmid DNA | |
| US4764279A (en) | Process for preparing the principal proteins of hemolyzed blood in the non-denatured form | |
| US4296025A (en) | Process for preparing human interferon | |
| US4597899A (en) | Process for obtaining a factor XIII preparation, and its use | |
| US3975344A (en) | Interferon purification | |
| CN102731642B (zh) | 从人血浆组分四沉淀制备高纯Apoa-I的生产工艺 | |
| JPH0244320B2 (ko) | ||
| JPH04505706A (ja) | 組み換えタンパク質の回収法 | |
| EP0089218B1 (en) | A process for purifying human chorionic gonadotropin | |
| US4526782A (en) | Process for recovering interferon | |
| JPS641118B2 (ko) | ||
| DE3750330T2 (de) | Verfahren zur Herstellung eines Impfstoffs gegen Hepatitis B. | |
| JPH0361440B2 (ko) | ||
| JPS6157290B2 (ko) | ||
| KR0140263B1 (ko) | 재조합 인간 인터페론 베타의 정제방법 | |
| KR100260631B1 (ko) | 활성형 인간 감마 인터페론의 제조방법 및 그에 의해 제조된 단백질 | |
| JPS60133887A (ja) | エラスタ−ゼの製法 | |
| RU2132386C1 (ru) | Способ получения рекомбинантного интерферона-гамма человека | |
| SU1161550A1 (ru) | Способ получени нуклеазы @ |